NC
RARE icon

nVerses Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

nVerses Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,700
Closed -$150K – 685
2024
Q3 		$150K Buy
2,700
+1,900
+238% +$96.8K 0.07% 394
2024
Q2 		$32.9K Buy
+800
New +$34.2K 0.02% 678

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

nVerses Capital's RARE Position: Q4 2024 in Review

nVerses Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2024, closing a stake of 2,700 shares — an estimated $150K sold.

nVerses Capital first reported a position in RARE in Q2 2024 and held it in 2 quarters. The position peaked at $150K in Q3 2024. 312 funds tracked by Wall St. Rank hold RARE as of Q4 2024.

  • nVerses Capital reported no remaining Ultragenyx Pharmaceutical position as of Q4 2024 after selling out during the quarter.
  • nVerses Capital sold 2,700 Ultragenyx Pharmaceutical shares in Q4 2024, an estimated $150K.
  • nVerses Capital first reported a position in Ultragenyx Pharmaceutical in Q2 2024 and held it in 2 quarters.
  • nVerses Capital's Ultragenyx Pharmaceutical position peaked at $150K in Q3 2024.
  • 312 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.